How do the five-year ublituximab OLE results influence your treatment paradigm with anti-CD20 drugs for multiple sclerosis?

The 5-year ublituximab OLE strengthens my approach to using anti-CD20/high-efficacy therapies early in relapsing MS, including ublituximab as a long-term option. I would still put these data in the context of individualized risk stratification, such as immunoglobulin monitoring, infection vigilance,...